Charm Therapeutics Secures $80M for AI-Driven Cancer Battle
September 7, 2025, 9:35 pm
Location: United Kingdom
Employees: 11-50
Founded date: 2021
Total raised: $130.11M
Location: United States, California, Palo Alto
Employees: 51-200
Founded date: 1977
Charm Therapeutics, a London-based biotech firm, clinched $80M in Series B funding. This investment fuels its AI-driven drug discovery platform. The company targets precision oncology, focusing on acute myeloid leukemia (AML). Its lead menin inhibitor aims to defeat treatment resistance, promising durable patient responses. New Enterprise Associates (NEA) and SR One led the round. OrbiMed, F-Prime, Khosla Ventures, and NVIDIA also invested. Strategic board appointments strengthen the team. Charm advances its innovative candidates toward clinical trials. This move signals a significant push against aggressive blood cancers. The company seeks to revolutionize patient outcomes with its next-generation therapies.
A pivotal moment arrives for oncology innovation. Charm Therapeutics, a leading biotechnology company, announced a significant financial milestone. The London-based firm secured $80 million in Series B funding. This capital injection propels its mission. It focuses on developing groundbreaking precision oncology treatments. The announcement marks a substantial vote of confidence in Charm’s approach.
This substantial funding round drew top-tier investors. New Enterprise Associates (NEA) and SR One co-led the investment. Existing backers also participated. These included OrbiMed, F-Prime, Khosla Ventures, and NVIDIA. Their continued support underscores Charm's promising trajectory. The investment will accelerate critical drug development initiatives.
Charm Therapeutics leverages a proprietary AI-driven drug discovery platform. This advanced technology is central to its strategy. The platform, named DragonFold, identifies novel therapeutic candidates. It streamlines the complex process of drug development. This AI-first approach aims for greater efficiency and precision. It seeks to unlock treatments for challenging diseases.
The company's lead program targets acute myeloid leukemia (AML). AML is an aggressive blood cancer. Patients often face poor prognoses. Current treatments frequently encounter limitations. Charm's menin inhibitor represents a new hope. It specifically addresses critical unmet needs in AML treatment.
First-generation menin inhibitors show promise. Yet, they face a significant hurdle: resistance mutations. Cancer cells rapidly evolve. They develop resistance, reducing treatment efficacy. This leads to relapse and disease progression. Patients desperately need more durable options. Charm Therapeutics addresses this directly.
Charm's next-generation candidates are different. They are designed to maintain potency. They target all known clinical resistance mutations. This is a crucial distinction. The goal is to deliver lasting responses for patients. The platform identifies molecules effective at low doses. It also avoids common safety risks, like QTc prolongation.
The company is advancing its lead menin inhibitor candidate. Clinical development begins early next year. This move marks a critical step. It transitions the therapy from preclinical stages to human trials. Success could transform outcomes for AML patients. It offers a new paradigm for fighting this devastating disease.
The Series B funding also brought new expertise to Charm's board. Matthew McAviney, M.D., from NEA, joins as a non-executive director. Mahesh Kudari, M.D., from SR One, also takes a board seat. Their insights will guide Charm’s strategic execution. This strengthens the company’s leadership as it nears clinical trials.
Further reinforcing its board, Charm added industry veterans. Briggs Morrison, M.D., now serves as a non-executive director. His extensive experience in menin inhibitor development is invaluable. He understands the AML therapeutic landscape deeply. Kim Blackwell, M.D., also joins the board. Her expertise in oncology and clinical development will prove critical.
Charm Therapeutics has now raised over $138 million in total funding. This substantial capital base positions the company strongly. It allows for sustained investment in its innovative pipeline. The focus remains on challenging cancers. The aim is to deliver truly transformative treatments.
The biotechnology sector continues its rapid evolution. AI is reshaping drug discovery. Charm Therapeutics stands at the forefront of this revolution. Its combination of advanced AI and deep biological understanding is powerful. It represents a new era in precision medicine.
This investment signifies more than financial backing. It validates Charm’s scientific approach. It confirms investor belief in its potential. The company’s focus on overcoming resistance mutations is key. This strategy could unlock therapies for other difficult-to-treat cancers.
Charm Therapeutics operates from London and Cambridge, UK. It embodies the global nature of biotech innovation. Its work has implications worldwide. The company’s commitment to patient-centric design is clear. Delivering durable responses remains its ultimate goal.
The journey from drug discovery to patient impact is long. It requires substantial resources. This Series B funding provides those resources. Charm is now poised for its next phase of growth. It moves closer to bringing its innovative therapies to those who need them most. The fight against treatment-resistant cancers gains a powerful new ally.
A pivotal moment arrives for oncology innovation. Charm Therapeutics, a leading biotechnology company, announced a significant financial milestone. The London-based firm secured $80 million in Series B funding. This capital injection propels its mission. It focuses on developing groundbreaking precision oncology treatments. The announcement marks a substantial vote of confidence in Charm’s approach.
This substantial funding round drew top-tier investors. New Enterprise Associates (NEA) and SR One co-led the investment. Existing backers also participated. These included OrbiMed, F-Prime, Khosla Ventures, and NVIDIA. Their continued support underscores Charm's promising trajectory. The investment will accelerate critical drug development initiatives.
Charm Therapeutics leverages a proprietary AI-driven drug discovery platform. This advanced technology is central to its strategy. The platform, named DragonFold, identifies novel therapeutic candidates. It streamlines the complex process of drug development. This AI-first approach aims for greater efficiency and precision. It seeks to unlock treatments for challenging diseases.
The company's lead program targets acute myeloid leukemia (AML). AML is an aggressive blood cancer. Patients often face poor prognoses. Current treatments frequently encounter limitations. Charm's menin inhibitor represents a new hope. It specifically addresses critical unmet needs in AML treatment.
First-generation menin inhibitors show promise. Yet, they face a significant hurdle: resistance mutations. Cancer cells rapidly evolve. They develop resistance, reducing treatment efficacy. This leads to relapse and disease progression. Patients desperately need more durable options. Charm Therapeutics addresses this directly.
Charm's next-generation candidates are different. They are designed to maintain potency. They target all known clinical resistance mutations. This is a crucial distinction. The goal is to deliver lasting responses for patients. The platform identifies molecules effective at low doses. It also avoids common safety risks, like QTc prolongation.
The company is advancing its lead menin inhibitor candidate. Clinical development begins early next year. This move marks a critical step. It transitions the therapy from preclinical stages to human trials. Success could transform outcomes for AML patients. It offers a new paradigm for fighting this devastating disease.
The Series B funding also brought new expertise to Charm's board. Matthew McAviney, M.D., from NEA, joins as a non-executive director. Mahesh Kudari, M.D., from SR One, also takes a board seat. Their insights will guide Charm’s strategic execution. This strengthens the company’s leadership as it nears clinical trials.
Further reinforcing its board, Charm added industry veterans. Briggs Morrison, M.D., now serves as a non-executive director. His extensive experience in menin inhibitor development is invaluable. He understands the AML therapeutic landscape deeply. Kim Blackwell, M.D., also joins the board. Her expertise in oncology and clinical development will prove critical.
Charm Therapeutics has now raised over $138 million in total funding. This substantial capital base positions the company strongly. It allows for sustained investment in its innovative pipeline. The focus remains on challenging cancers. The aim is to deliver truly transformative treatments.
The biotechnology sector continues its rapid evolution. AI is reshaping drug discovery. Charm Therapeutics stands at the forefront of this revolution. Its combination of advanced AI and deep biological understanding is powerful. It represents a new era in precision medicine.
This investment signifies more than financial backing. It validates Charm’s scientific approach. It confirms investor belief in its potential. The company’s focus on overcoming resistance mutations is key. This strategy could unlock therapies for other difficult-to-treat cancers.
Charm Therapeutics operates from London and Cambridge, UK. It embodies the global nature of biotech innovation. Its work has implications worldwide. The company’s commitment to patient-centric design is clear. Delivering durable responses remains its ultimate goal.
The journey from drug discovery to patient impact is long. It requires substantial resources. This Series B funding provides those resources. Charm is now poised for its next phase of growth. It moves closer to bringing its innovative therapies to those who need them most. The fight against treatment-resistant cancers gains a powerful new ally.